Back
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals develops medicines using RNA-targeted therapies to treat diseases. The company is advancing clinical and preclinical programs, including REDEMPLO for commercialization, along with partnership and licensing arrangements to support its research and development pipeline.
$73.48+429.01%1Y
ARWR · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Severe Hypertriglyceridemia
Phase 3Familial Chylomicronemia
Plozasiran is a siRNA conjugated with GalNAc that degrades the apoC-III mRNA through the RNA interference mechanism resulting in reduced levels of hepatic and serum apoC-III protein.
Phase 3Homozygous Familial Hypercholesterolemia
Phase 2Homozygous Familial Hypercholesterolemia
Phase 2Hyperlipidemia; Mixed
Phase 2Myotonic Dystrophy 1
Phase 2Myotonic Dystrophy 1
Phase 2Facio-Scapulo-Humeral Dystrophy
Phase 2obesity
Phase 2Asthma
Phase 2obesity
Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.